Gene interactions and pathways from curated databases and text-mining

◀ Back to CXCL12

CXCL12 — CXCR5

Pathways - manually collected, often from reviews:

Text-mined interactions from Literome

Amara et al., J Biol Chem 1999 : Importantly, the amino-terminal domain of SDF-1alpha which is required for binding to, and activation of, CXCR4 remains exposed after binding to HS and is recognized by a neutralizing monoclonal antibody directed against the first residues of the chemokine
Chan et al., Ophthalmology 2003 (Lymphoma, B-Cell...) : CXCR4 and CXCR5 transcripts were detected abundantly in lymphoma cells, whereas BLC and SDF-1 transcripts were detected only in the RPE and not the malignant cells
Hu et al., Circulation 2007 (Anoxia...) : In isolated myocytes, CXCR4 activation by SDF-1alpha resulted in increased phosphorylation of both ERK 1/2 and AKT and decreased phosphorylation of JNK and p38
Sierro et al., Proc Natl Acad Sci U S A 2007 : CXCL12 did not induce signaling through CXCR7 ; however, CXCR7 formed functional heterodimers with CXCR4 and enhanced CXCL12 induced signaling
Pandruvada et al., Int J Cancer 2010 (Carcinoma, Squamous Cell...) : Interestingly, CXCL13 treatment to OSCC cells induced CXCR5 and MMP-9 expression suggesting an autocrine regulatory function in OSCC cells
Duda et al., Clin Cancer Res 2011 (Neoplasms) : CXCL12 ( SDF1alpha ) -CXCR4/CXCR7 pathway inhibition : an emerging sensitizer for anticancer therapies ?
Mueller et al., PloS one 2013 (Immunologic Deficiency Syndromes...) : Upon stimulation by the endogenous ligand CXCL12 , CXCR4 becomes phosphorylated at multiple sites in its C-terminal domain